Document Detail

Conversions from captopril to lisinopril at a dosage ratio of 5:1 result in comparable control of hypertension.
MedLine Citation:
PMID:  8773158     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To provide clinical support that conversion from captopril to lisinopril at a daily oral dosage ratio of 5:1 maintains comparable therapeutic efficacy, and to estimate retrospectively cost savings because of conversion from captopril to lisinopril therapy at the study site and with the associated overall drug conversion program instituted by Kaiser Permanente. DESIGN: An open-label, randomized, prospective, parallel study was performed in 56 patients with mild-to-moderate hypertension. In a 4-week preroandomization period, oral maintenance dosages of captopril were established. Patients then were randomly assigned either to continue taking captopril or to change to lisinopril at an initial conversion ratio of captopril 5 mg to lisinopril 1 mg. Blood pressures were evaluated 2, 4, 8, and 12 weeks postrandomization. If necessary, dosages were adjusted to maintain adequate efficacy (i.e., systolic pressure < 160 mm Hg and diastolic pressure < 90 mm Hg in the prerandomization period; diastolic pressure < 90 mm Hg postrandomization). Cost savings for the study site and to the overall program with respect to conversion from captopril were defined as the difference between the estimated drug costs and the drug costs projected if the conversion had not been made. SETTING: Woodland Hills Medical Center of the Southern California Region of Kaiser Permanente Medical Care Program. MAIN OUTCOME MEASURES: The main outcome measures were systolic and diastolic blood pressure. The measure for the retrospective cost savings analysis was estimated cost savings based on the number of prescriptions written for captopril and lisinopril from December 1988 through December 1993, and the average wholesale price. PARTICIPANTS: Members of the Kaiser Permanente Medical Care Program who were diagnosed with mild-to-moderate hypertension and whose hypertension was controlled by captopril alone. Retrospectively, mild-to-moderate hypertension would have been classified as stages 1-3, based on the current guidelines of the Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. RESULTS: The blood pressures of patients in whom captopril therapy was switched to lisinopril therapy were maintained throughout the entire study within the defined acceptable limits of control when the conversion was initiated at a daily oral dosage ratio of 5:1. The final dosage conversion ratio was not significantly different statistically from the theoretical dosage conversion ratio of 5:1. CONCLUSIONS: The conversion from captopril (in equally divided daily doses) to lisinopril (once daily) at a dosage ratio of 5:1 maintained comparable control of mild-to-moderate hypertension with no increase in adverse effects. In addition, the cost savings associated with an overall drug conversion program were substantial, and the conversion provided a preferred once-daily dosing regimen.
T H Gill; F Hauter; M A Pelter
Related Documents :
20030528 - Effect of spironolactone on urinary protein excretion in patients with chronic kidney d...
7943408 - Restraining effects of captopril on sympathetic excitatory responses in dogs: a spectra...
7026198 - Captopril withdrawal after chronic therapy.
11903508 - Non-contribution of renin-angiotensin system to pressor response to n(g)-nitro-l-argini...
10845348 - Do the daily experiences of healthy men and women vary according to occupational presti...
22166588 - The influence of decreased low-molecular-weight heparin nadroparin dose on diastolic bl...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  The Annals of pharmacotherapy     Volume:  30     ISSN:  1060-0280     ISO Abbreviation:  Ann Pharmacother     Publication Date:  1996 Jan 
Date Detail:
Created Date:  1996-10-09     Completed Date:  1996-10-09     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9203131     Medline TA:  Ann Pharmacother     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  7-11     Citation Subset:  IM    
Kaiser Permanente Medical Center, Woodland Hills, CA 91367, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiotensin-Converting Enzyme Inhibitors / administration & dosage*,  economics,  therapeutic use
Blood Pressure / drug effects
Captopril / administration & dosage*,  economics,  therapeutic use
Drug Costs
Hypertension / drug therapy*,  physiopathology
Lisinopril / administration & dosage*,  economics,  therapeutic use
Middle Aged
Prospective Studies
Retrospective Studies
Treatment Outcome
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 62571-86-2/Captopril; 83915-83-7/Lisinopril

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Precocious cerebral development associated with agenesis of the corpus callosum in mid-fetal life: a...
Next Document:  Population pharmacodynamics: strategies for concentration-and effect-controlled clinical trials.